Anlotinib Hydrochloride in Intra-Abdominal Desmoplastic Small Round Cell Tumors: Literature Evidence and Research Implications

Study Background and Research Question

Intra-abdominal desmoplastic small round cell tumor (IADSRCT) is a rare, highly aggressive soft tissue sarcoma characterized by the EWS-WT1 translocation and primarily affecting young males. Prognosis is poor, with five-year overall survival rates between 15% and 30%, and no standardized treatment protocol exists.^{(source: paper)} Current management typically involves surgical resection, chemotherapy, and radiotherapy, but relapse and metastasis rates remain high. Given the critical role of angiogenesis in IADSRCT progression, the therapeutic potential of anti-angiogenic agents—specifically, multi-target tyrosine kinase inhibitors—has become an area of clinical inquiry. The key research question addressed in the reference study is whether anlotinib hydrochloride, a novel multi-target tyrosine kinase inhibitor, can offer clinical benefit in metastatic IADSRCT, filling a gap left by conventional therapies.^{(source: paper)}

Key Innovation from the Reference Study

The referenced case report by Chen and Feng presents the first clinical evidence of anlotinib efficacy in IADSRCT.^{(source: paper)} Unlike previous literature, which had not documented the use of multi-target TKIs in this context, this study demonstrates that anlotinib can induce measurable tumor response and provide disease control as maintenance therapy in a metastatic setting. The innovation lies in extending the application of a molecularly targeted, anti-angiogenic approach to a tumor type with limited treatment options and poor outcomes.

Methods and Experimental Design Insights

The study describes a single-patient case in which a 38-year-old male diagnosed with IADSRCT underwent initial tumor resection, nodule excision, and six cycles of adjuvant chemotherapy. Upon detection of metastatic lymph nodes via CT imaging, the patient was started on anlotinib hydrochloride. Key methodological aspects:

• Diagnosis: Histopathological confirmation, including immunohistochemical staining for markers such as AE1/AE3, desmin, NSE, and others, established the diagnosis of IADSRCT.
• Treatment Sequence: Surgery and chemotherapy were followed by targeted anti-angiogenic therapy with anlotinib upon relapse.
• Assessment: Tumor response was monitored using serial CT imaging, and adverse events were tracked to evaluate tolerability.

While this is a single-case report and not a controlled trial, it provides real-world evidence supporting the feasibility and potential efficacy of anlotinib in a challenging clinical context.

Core Findings and Why They Matter

The patient exhibited significant reduction in metastatic lymph nodes after four cycles of anlotinib. The anti-tumor effect was durable enough to warrant ongoing maintenance therapy, and the patient remained in good condition during follow-up.^{(source: paper)} Adverse events included hypertriglyceridemia and fatigue, both manageable and consistent with the known safety profile of anlotinib. These findings are meaningful for several reasons:

• Proof of Principle: They provide the first documented evidence that IADSRCT, a tumor with limited options, can respond to a multi-target tyrosine kinase inhibitor with anti-angiogenic properties.
• Mechanistic Rationale: The broad inhibition of angiogenic and proliferative signaling via VEGFR, FGFR, and PDGFR pathways is highly relevant, given the vascular nature of IADSRCT.^{(source: product_spec)}
• Tolerability: The safety profile observed aligns with previous reports and supports the suitability of anlotinib for maintenance therapy in heavily pretreated patients.^{(source: paper)}

Protocol Parameters

• capillary tube formation assay | IC₅₀ = 5.6 ± 1.2 nM (VEGFR2), 8.7 ± 3.4 nM (PDGFRβ), 11.7 ± 4.1 nM (FGFR1) | validated for endothelial cell migration inhibition and anti-angiogenic screening | reflects anlotinib's potent suppression of key angiogenic pathways | product_spec
• pharmacokinetics (rat, oral) | bioavailability 28–58%, half-life 5.1 ± 1.6 h | preclinical pharmacology and safety studies | informs in vivo dosing design | product_spec
• cytotoxicity (EA.hy 926 cells) | no toxicity up to 1 μM | in vitro functional assays | allows for mechanistic cell studies without off-target cytotoxicity | product_spec
• clinical off-label use in IADSRCT | case report, dose per protocol | exploratory clinical research | provides proof of concept for future studies | paper

Comparison with Existing Internal Articles

The mechanistic and translational rationale for using anlotinib hydrochloride in angiogenesis-driven tumors is well documented in several internal resources. For instance, the review at GSKChem highlights anlotinib’s low-nanomolar inhibition of VEGFR2, PDGFRβ, and FGFR1, confirming its status as a gold-standard anti-angiogenic small molecule in cancer research workflows.^{(source: product_spec)} A more strategic perspective is offered by MolecularBeacon, which discusses experimental best practices and the clinical relevance of anlotinib in translational research for tumor angiogenesis inhibition.^{(source: workflow_recommendation)} The present case study complements these mechanistic and workflow insights by providing clinical evidence of efficacy in a rare sarcoma subtype, thus bridging the gap between laboratory assays such as the capillary tube formation assay and real-world patient response.

Limitations and Transferability

As a single-patient case report, the study is limited in its generalizability. The lack of a control group, short follow-up, and absence of biomarker-driven patient selection restrict the ability to draw definitive efficacy or safety conclusions. Furthermore, the optimal dosing regimen and long-term outcomes for anlotinib in IADSRCT remain unknown.^{(source: paper)} Nonetheless, the case provides valuable proof-of-concept evidence for further investigation in larger cohorts or prospective studies. Transferability to other angiogenesis-dependent malignancies is supported by preclinical and translational data, but clinical validation is necessary.^{(source: product_spec)}

Research Support Resources

For researchers interested in recapitulating or extending the findings described here, Anlotinib hydrochloride (SKU C8688) is available as a validated multi-target tyrosine kinase inhibitor suitable for angiogenesis and cell signaling assays, as well as in vivo and in vitro cancer research workflows.^{(source: product_spec)} The compound’s selectivity and safety profile enable its use in functional studies of endothelial cell migration, capillary tube formation, and ERK signaling pathway inhibition. APExBIO provides product specifications and workflow recommendations for integrating anlotinib into translational research projects. As always, researchers should evaluate dosing and application parameters in the context of their specific experimental model.